Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06541405
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, Shanghai, China
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06541444
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Shanghai, Shanghai, China
Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06117878
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
Safety and Efficacy of NK510 to Treat Gastric Cancer
Early Phase 1
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06098898
- Locations
- 🇨🇳
Shanghai Tenth People's Hospital, Shanghai, China
Safety and Efficacy of NK510 to Treat NSCLC
Early Phase 1
Recruiting
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06097962
- Locations
- 🇨🇳
General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China
© Copyright 2025. All Rights Reserved by MedPath